These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 23358983

  • 1. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
    Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T.
    J Clin Oncol; 2013 Mar 20; 31(9):1149-56. PubMed ID: 23358983
    [Abstract] [Full Text] [Related]

  • 2. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA.
    N Engl J Med; 1999 Jul 29; 341(5):305-11. PubMed ID: 10423464
    [Abstract] [Full Text] [Related]

  • 3. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H.
    N Engl J Med; 1999 Jul 29; 341(5):312-8. PubMed ID: 10423465
    [Abstract] [Full Text] [Related]

  • 4. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S, Kollaras P, Giannakakis T, Seitanidis B, Kordosis T, Nikolaidis J, Hatzitolios A, Nikolaidis P.
    Eur J Intern Med; 2008 Dec 29; 19(8):619-24. PubMed ID: 19046729
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR, STIC Study Group.
    Infection; 2009 Oct 29; 37(5):407-17. PubMed ID: 19768381
    [Abstract] [Full Text] [Related]

  • 6. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA.
    Cancer; 2005 Jun 15; 103(12):2629-35. PubMed ID: 15856427
    [Abstract] [Full Text] [Related]

  • 7. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
    Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P.
    Support Care Cancer; 2008 Sep 15; 16(9):1017-23. PubMed ID: 18197434
    [Abstract] [Full Text] [Related]

  • 8. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T.
    Med Pediatr Oncol; 2003 Feb 15; 40(2):93-8. PubMed ID: 12461792
    [Abstract] [Full Text] [Related]

  • 9. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
    Heystek M, Ross JD, PID Study Group.
    Int J STD AIDS; 2009 Oct 15; 20(10):690-5. PubMed ID: 19815913
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
    Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Böll B, Kaul I, Wassmer G, Hallek M, Scheid C, Cornely OA.
    Int J Antimicrob Agents; 2012 Feb 15; 39(2):130-4. PubMed ID: 22169408
    [Abstract] [Full Text] [Related]

  • 11. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E, Bodmer N, Simon A, Leibundgut K, Kühne T, Niggli FK, Ammann RA.
    Pediatr Blood Cancer; 2012 Sep 15; 59(3):423-30. PubMed ID: 22271702
    [Abstract] [Full Text] [Related]

  • 12. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
    Ross JD, Cronjé HS, Paszkowski T, Rakoczi I, Vildaite D, Kureishi A, Alefelder M, Arvis P, Reimnitz P, MAIDEN Study Group.
    Sex Transm Infect; 2006 Dec 15; 82(6):446-51. PubMed ID: 16723364
    [Abstract] [Full Text] [Related]

  • 13. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 14. Topical ciprofloxacin/dexamethasone superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea through tympanostomy tubes.
    Dohar J, Giles W, Roland P, Bikhazi N, Carroll S, Moe R, Reese B, Dupre S, Wall M, Stroman D, McLean C, Crenshaw K.
    Pediatrics; 2006 Sep 15; 118(3):e561-9. PubMed ID: 16880248
    [Abstract] [Full Text] [Related]

  • 15. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, Gómez C, Ruiz A, García-Carbonero R, Cortés-Funes H.
    Cancer; 1999 Jan 01; 85(1):213-9. PubMed ID: 9921995
    [Abstract] [Full Text] [Related]

  • 16. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
    Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M.
    J Clin Oncol; 2006 Sep 01; 24(25):4129-34. PubMed ID: 16943529
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S.
    J Pediatr Hematol Oncol; 2009 Sep 01; 31(9):635-41. PubMed ID: 19684522
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K.
    Int J Antimicrob Agents; 2005 Dec 01; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [Abstract] [Full Text] [Related]

  • 20. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA, Mösges R, Desrosiers M, Haverstock D, van Veenhuyzen D, Herman-Gnjidic Z.
    Laryngoscope; 2010 May 01; 120(5):1057-62. PubMed ID: 20422704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.